Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Chief Commercial Officer | January 31, 2020 | February 04, 2020 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | EVP, Head of North America | August 13, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date January 31, 2020 · Filed February 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.26 · Expires 2030-01-30 | Direct | 125,000 |
Reported balance
After 2020-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-31 · Grant · Acquired 125,000 · Balance 125,000 F1: The options vest ratably over a four-year period beginning on January 20, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest ratably over a four-year period beginning on January 20, 2020.
RHYTHM PHARMACEUTICALS, INC.
Report date August 13, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-08-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-13 · Exercise / conversion · Acquired 35,000 · Balance 54,233 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. Row 2 · 2026-08-13 · Exercise / conversion · Acquired 21,601 · Balance 75,834 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. Row 3 · 2026-08-13 · Sale · Disposed 75,834 · Balance 0 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.29 · Expires 2030-11-09 | Direct | 36,283 |
Reported balance
After 2026-08-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-13 · Exercise / conversion · Disposed 35,000 · Balance 36,283 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F2: The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2032-02-08 | Direct | 0 |
Reported balance
After 2026-08-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-13 · Exercise / conversion · Disposed 21,601 · Balance 0 F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F3: The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.
F2: The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
F3: The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 14, 2026 23:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 21,601 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001649904-26-000009 · form4.xml · derivative · entry 5 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,601 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 23:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $24.29 | $0.00 |
DisclosureSEC source: 0001649904-26-000009 · form4.xml · derivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,283 Underlying: Common Stock · 35,000 shares Expires 2030-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. F2 · derivative.exercise_date: The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 23:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 75,834 | $117.38 | $8,901,531.42 |
DisclosureSEC source: 0001649904-26-000009 · form4.xml · nonDerivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 23:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 21,601 | $6.80 | $146,886.80 |
DisclosureSEC source: 0001649904-26-000009 · form4.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 23:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 35,000 | $24.29 | $850,150.00 |
DisclosureSEC source: 0001649904-26-000009 · form4.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $98.47 | $0.00 |
DisclosureSEC source: 0001104659-26-015399 · tm266366-4_4seq1.xml · derivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2036-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 21,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-015399 · tm266366-4_4seq1.xml · derivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,650 Underlying: Common Stock · 21,650 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:33 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 9,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009767 · tm264963-4_4seq1.xml · derivative · entry 6 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,487 Underlying: Common Stock · 9,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:33 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009767 · tm264963-4_4seq1.xml · derivative · entry 5 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:33 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009767 · tm264963-4_4seq1.xml · derivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,512 Underlying: Common Stock · 4,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:33 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009767 · tm264963-4_4seq1.xml · derivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:33 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Tax withholdingCommon Stock | 9,237 | $108.99 | $1,006,740.63 |
DisclosureSEC source: 0001104659-26-009767 · tm264963-4_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,233 F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:33 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 22,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-009767 · tm264963-4_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,035 | $57.22 | $116,442.70 |
DisclosureSEC source: 0001104659-25-015320 · tm257103-4_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,858 F2 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015320 · tm257103-4_4seq1.xml · derivative · entry 5 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-015320 · tm257103-4_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $56.69 | $0.00 |
DisclosureSEC source: 0001104659-25-015320 · tm257103-4_4seq1.xml · derivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-02-13 F4 · derivative.exercise_date: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 36,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015320 · tm257103-4_4seq1.xml · derivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,650 Underlying: Common Stock · 36,650 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 21:55 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,205 | $58.00 | $69,890.00 |
DisclosureSEC source: 0001104659-25-014257 · tm256729-1_4seq1.xml · nonDerivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,393 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:55 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,205 | $56.39 | $67,949.95 |
DisclosureSEC source: 0001104659-25-014257 · tm256729-1_4seq1.xml · nonDerivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,598 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:55 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 10 | $56.41 | $564.10 |
DisclosureSEC source: 0001104659-25-014257 · tm256729-1_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,803 F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:55 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 600 | $56.39 | $33,834.00 |
DisclosureSEC source: 0001104659-25-014257 · tm256729-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,813 F1 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · derivative · entry 10 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,031 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F8 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F8 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 4 | $57.50 | $230.00 |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · nonDerivative · entry 7 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,413 F5 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,023 | $57.51 | $58,832.73 |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · nonDerivative · entry 6 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,417 F5 · kind: The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,031 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · nonDerivative · entry 5 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,295 | $59.34 | $136,187.14 |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · nonDerivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,409 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $59.1400 to $59.3600 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,894 | $58.39 | $110,595.96 |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · nonDerivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,704 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $58.0750 to $58.8900 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,189 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · derivative · entry 9 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,601 Underlying: Common Stock · 4,189 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · derivative · entry 8 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,437 Underlying: Common Stock · 3,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,189 | $6.80 | $28,485.20 |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-011677 · tm256299-3_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 200 | $61.95 | $12,390.00 |
DisclosureSEC source: 0001104659-25-010610 · tm255903-1_4seq1.xml · nonDerivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 972 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,133 | $61.01 | $69,129.66 |
DisclosureSEC source: 0001104659-25-010610 · tm255903-1_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,172 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $60.67 to $61.49. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,733 | $60.08 | $104,120.55 |
DisclosureSEC source: 0001104659-25-010610 · tm255903-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,305 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $59.54 to $60.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 02:23 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,447 | $59.43 | $85,995.21 |
DisclosureSEC source: 0001104659-25-009284 · tm255457-2_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,038 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 02:23 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-009284 · tm255457-2_4seq1.xml · derivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,024 Underlying: Common Stock · 4,513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 02:23 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-009284 · tm255457-2_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,642 | $0.00 Strike: $30.66 | $0.00 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · derivative · entry 10 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,108 Underlying: Common Stock · 11,642 shares Expires 2031-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,717 | $0.00 Strike: $24.29 | $0.00 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · derivative · entry 9 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,283 Underlying: Common Stock · 28,717 shares Expires 2030-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock options were granted on November 9, 2020. The options are fully vested. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,622 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · derivative · entry 8 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,790 Underlying: Common Stock · 20,622 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 200 | $68.43 | $13,686.00 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · nonDerivative · entry 7 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 972 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 11,070 | $67.56 | $747,872.60 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · nonDerivative · entry 6 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,172 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $67.33 to $68.3299 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 17,540 | $66.95 | $1,174,274.94 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · nonDerivative · entry 5 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,242 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $66.33 to $67.3299 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 38,051 | $65.68 | $2,499,048.89 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · nonDerivative · entry 4 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,782 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.18 to $66.1799 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 11,642 | $30.66 | $356,943.72 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · nonDerivative · entry 3 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 28,717 | $24.29 | $697,535.93 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:04 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 20,622 | $6.80 | $140,229.60 |
DisclosureSEC source: 0001104659-24-117942 · tm2428383-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 20:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 9,066 | $39.33 | $356,565.78 |
DisclosureSEC source: 0001104659-24-037880 · tm249484-1_4seq1.xml · nonDerivative · entry 2 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,852 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $38.75 to $39.72. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 20:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 9,169 | $38.22 | $350,439.18 |
DisclosureSEC source: 0001104659-24-037880 · tm249484-1_4seq1.xml · nonDerivative · entry 1 Lee Jennifer Kayden · CIK 0001801372 · EVP, Head of North America 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,918 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $37.75 to $38.68. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.